Prelude Therapeutics Inc. reports financial results for the third quarter of 2025 and updates on pipeline progress. Their lead candidate for the mutant selective JAK2V617F inhibitor program is advancing towards clinical trials with an expected IND filing in the first quarter of 2026. The oral KAT6A degrader program’s lead candidate is also advancing with an IND filing expected in mid-2026.
Preclinical data from both the JAK2V617F inhibitor program and CALR-targeted degrader antibody conjugate program have been accepted for oral presentations at the ASH 67th Annual Meeting. The company’s current cash runway is estimated to extend into 2027.
Prelude Therapeutics plans to host an investor conference call and webcast on November 12, 2025, at 8:00 AM EST to discuss their recent strategic updates and pipeline progress. The company aims to target clinically validated mechanisms with their innovative precision oncology treatments.
Their JAK2V617F inhibitor program focuses on a mutation that impacts a significant percentage of patients with myeloproliferative neoplasms. The lead candidate has shown mutant-specific inhibition in preclinical models and is set to enter clinical trials in 2026. Preclinical data from the program will be presented at the ASH 67th Annual Meeting.
In addition to their JAK2V617F program, Prelude is also advancing an oral KAT6A degrader program for the treatment of ER+ breast cancer. They have selected a development candidate and plan to file an IND in mid-2026. The company aims to improve efficacy, tolerability, and combinability with their selective degraders.
Prelude is leveraging their expertise in targeted protein degradation to develop novel degrader payloads for next-generation DACs. They have expanded their collaboration with AbCellera Biologics to utilize degrader payloads on additional antibody targets. Preclinical data has shown potential for improved in vivo efficacy and tolerability.
The company is exploring a mutated calreticulin DAC discovery program for patients with CALR mutations in myelofibrosis and essential thrombocythemia. They presented preclinical data at the EHA 2025 Congress and will share updated data at the ASH 67th Annual Meeting in December.
Financially, Prelude reported cash, cash equivalents, restricted cash, and marketable securities totaling $58.2 million at the end of September 2025. They anticipate their existing funds to support operations into 2027. Research and development expenses decreased in the third quarter of 2025 compared to the prior year period.
To learn more about Prelude Therapeutics and their innovative precision oncology treatments, interested parties can access the company’s corporate presentation on their website. The company will host a conference call and webcast on November 12, 2025, to provide further updates on their progress and financial results.
Read more at GlobeNewswire: Prelude Therapeutics Reports Third Quarter 2025 Financial